Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential

Praxis Precision Medicines, Inc. remains a Strong Buy, driven by two NDA submissions and pipeline expansion opportunities targeting essential tremor and developmental and epileptic encephalopathies. The company's relutrigine achieved a 46% placebo-adjusted reduction in motor seizure frequency for SCN2A/SCN8A DEE and is under FDA priority review with a PDUFA date of September 27, 2026. Pipeline expansion includes relutrigine's potential sNDA for broad DEE and elsunersen for early-onset SCN2A DEE, with key data readouts expected in 2026–2027.